← Issue №3/ week of Jul 19, 2026/Hepatology

Clonal diversity underpins distinct modes of recurrence in hepatocellular carcinoma: the PLANet cohort study.

From GI Signals issue №3: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=24 · Jul 21, 2026 · Gut · IF 24.6

Clonal diversity underpins distinct modes of recurrence in hepatocellular carcinoma: the PLANet cohort study.

Basic sciencehepatocellular carcinomabasic sciencetranslationalbiomarker
Clinical takeawayNo direct clinical action yet. This mechanistic study reveals how clonal architecture and immunosuppression determine recurrence patterns and suggests checkpoint inhibitors may be more effective against polyclonal tumors, but prospective validation of the predictive model and treatment strategies are required before clinical implementation.
What it foundMore than 50% of intrahepatic HCC recurrences showed polyclonal seeding (multiple subclones) with early recurrence, whereas most distant metastases were monoclonal from a dominant C5/C6 subclone; a multi-omics model predicted recurrence with 86% accuracy (AUC 0.86).
ContextHCC recurrence risk stratification after curative resection lacks biologic mechanistic insight. This work identifies polyclonal spread (enabled by regulatory T cell enrichment) as distinct from monoclonal metastatic spread and challenges the single dominant-clone model, potentially enabling future risk assessment and treatment personalization.
Measured against the standard of care· AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834)

Decision at stakepost-resection surveillance strategy and risk stratification for recurrence in HCC patients after curative-intent resection

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. Do not surveil patients whose life expectancy is <1-2 years from comorbidity that neither transplantation nor HCC therapy can remedy, and weigh the physical, psychological and financial harms of surveillance case by case. Also surveil selected non-cirrhotic chronic HBV carriers: Asian men >40 and women >50 from endemic regions, people of African origin at younger ages, family history of HCC, or high viral load/active hepatitis. AGA 2026 endorses PAGE-B (intermediate/high risk at ≥10) and REAL-B to stratify these patients. Patients with HCV cirrhosis stay in surveillance after SVR. Patients without cirrhosis from other causes are NOT surveilled because incidence is too low (≤F3 fibrosis, MASLD without cirrhosis, HCV cured before cirrhosis), though fibrosis staging uncertainty warrants individual discussion. CT/MRI are not routine surveillance tools. Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. Multicancer blood detection tests should not be used. AGA 2026 states that preventing cirrhosis (treating viral hepatitis, metabolic disease and alcohol use disorder) is the most effective way to reduce HCC deaths. Recall per AASLD 2023: AFP ≥20 ng/mL or a rising AFP (doubling, or a rise on two consecutive tests even below 20), any ultrasound observation ≥1 cm, or an inadequate ultrasound triggers multiphasic contrast CT or MRI read with LI-RADS. Treatment per AASLD 2023 is BCLC-linked: resection, ablation or transplant within Milan criteria for very-early/early disease, TACE and other locoregional therapy for intermediate disease, systemic therapy for advanced disease. Preferred first-line systemic therapy in Child-Pugh A is atezolizumab+bevacizumab or durvalumab+tremelimumab (STRIDE); sorafenib, lenvatinib or durvalumab monotherapy are the alternatives. BEACON-HCC (AASLD/HCC-LIVE, Hepatology, online August 2026) is a modified-Delphi North American consensus framework for treatment allocation. It weighs tumor burden, vascular invasion, tumor biology, liver function and local-therapy availability, and it complements BCLC without replacing it. In its 29-case pilot it matched multidisciplinary decisions 96.6% of the time and BCLC 2025 72.4% of the time. Under BEACON-HCC, macrovascular invasion does not automatically mean systemic therapy, and EBRT/SBRT and TARE are primary options. Continue post-treatment surveillance with contrast-enhanced cross-sectional imaging early after curative therapy.

AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834) · reviewed 2026-10-25 ↗
Zhang Y … Tam WL · Gut · IF 24.6 · PubMed ↗Permalink
← Read the whole of issue №3 Every paper GI Signals surfaces gets a page like this one. All issues